Blockchain Registration Transaction Record

Oncotelic to Present at OTCQB Conference, Highlighting Everolimus Trial and AI Platforms

Oncotelic Therapeutics (OTLC) to present at OTCQB Virtual Investor Conference, highlighting Everolimus trial progress and AI-driven platforms. Learn about the latest advancements.

This announcement matters because it signals Oncotelic's continued progress in advancing its oncology pipeline, particularly the Phase 1b Everolimus trial, which could lead to new treatment options for cancer patients. The company's focus on AI-driven drug discovery and nanomedicine platforms positions it at the forefront of innovative cancer therapies, potentially improving patient outcomes and offering investors a glimpse into the future of precision medicine.